前CytoDyn首席执行官被判入狱,需支付530万美元赔偿,而前CRO负责人赢得新审判。
Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial
生物技术与制药领域的最新动态
Ex-CytoDyn CEO sentenced to prison, must pay $5.3M restitution as former CRO leader wins new trial
European investment firm Gimv calls it quits on new life science financing
New rules, higher stakes: Biopharma plays the long game in 2026
Feds charge former Zynex execs in massive medtech billing fraud case
Guardant Health gets FDA nod to expand use of blood test for colon cancer
AstraZeneca keeps UK research site on pause, but options open
Fortitude has faith molecular glue degraders can overcome ADC resistance
'Things are looking up': British biotechs consider going public after yearslong IPO drought
Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials
Abbott shares sag as global diagnostic, nutrition business sales declines drag on earnings
Chutes & Ladders—BMS snags top neuro researcher from Eisai
J. Craig Venter launches genomics startup designed to boost diagnostic insights
Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout
NIH imposes full ban of aborted fetal tissue in research
BMS pens $850M solid tumor pact with T-cell engager biotech Janux
Corcept racks up phase 3 cancer win to bounce back from FDA Cushing's rejection
Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
Hoth strikes back against cancer drug skin toxicities, but share price stays frozen
Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma